Patients
We aim to build resilient healthcare solutions that help patients—especially in underserved communities—live better every day.
A key mission pillar is expanding global access to life-saving biologics by making high-quality, affordable biosimilars widely available. Lower pricing compared to reference products reduces out-of-pocket costs, enhancing affordability. We also run programs to support patients across diverse economic backgrounds.
Increasing biosimilar access for NCDs like cancer and diabetes can lower mortality rates and supports UN SDG 3.4: reducing premature NCD deaths by one-third by 2030—especially vital for low-and middle-income countries (LMICs) facing high disease burdens and economic strain.
Expanding Access to High-Quality Insulins
Insulin is vital for people with diabetes, yet many are denied access due to high costs. As a leading global insulin manufacturer, we are committed to universal access, aiming to reach one in five insulin-dependent patients worldwide.
Our innovation-led strategy focuses on affordability, using global manufacturing capacity to expand access. Our robust portfolio of human insulin and analogs serves millions globally, including in the US, Europe, Mexico, and Malaysia, where we meet much of the national demand.
Since 2004, we have addressed insulin inequity by launching an indigenously developed human insulin in India at a fraction of the cost of imported options.
Insulin Donations for Patients in LMICs
- In FY24, we partnered with Insulin for Life, a U.S.-based non-profit supporting diabetes care in underserved regions.
- Donated ~12,500 Insulin Glargine injection pens and 1,000 bGlargine vials.
- Supplies were distributed to clinics and hospitals treating all forms of diabetes (Type 1, Type 2, gestational).
- Focused on reaching patients in low- and middle-income countries (LMICs).
Bridging Gap in Diabetes Care in Ethiopia
We are supporting a multi-year project ‘Embedding Specialist Nurses in Diabetes Care’, which is being implemented by Diabetes Africa and St Paul’s Hospital Millennium Medical College in Ethiopia. This project aims to upskill nurses to become diabetes specialists to bridge the shortage of healthcare professionals trained to treat diabetes in Ethiopia.
Facilitating Access to Cancer Treatment
We are leading the fight against cancer by offering cost-effective, high-quality anti-cancer biosimilars as alternatives to expensive biologics. Our therapies cover cancer of breast, head and neck, colorectal, ovarian, cervical, kidney, brain, lung, and supportive care.
- Launched the world’s first biosimilar Trastuzumab for HER2-positive breast cancer in India in 2014, expanding global access since.
- Partnering with Clinton Health Access Initiative (CHAI), under the Cancer Assistance Partnership (CAP), and the Ministries of Health in Nigeria and Tanzania to provide anti-cancer therapies at access prices*.
- Working with global partners and health systems to lower costs, improve access, and enhance cancer care quality.
*Government Mediated Access Price (GMAP) is a policy where the government negotiates to lower drug prices with pharma companies to improve accessibility to the population.
